Evaxion Biotech Files 6-K, Confirms 20-F Reporting
Ticker: EVAX · Form: 6-K · Filed: Apr 28, 2025 · CIK: 1828253
| Field | Detail |
|---|---|
| Company | Evaxion Biotech A/S (EVAX) |
| Form Type | 6-K |
| Filed Date | Apr 28, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 6-k, foreign-private-issuer
Related Tickers: EVAX
TL;DR
Evaxion Biotech (EVAX) filed a routine 6-K, confirming they're a foreign private issuer using 20-F for annual reports. No new info.
AI Summary
Evaxion Biotech A/S, a biotechnology company, filed a Form 6-K on April 28, 2025. This report is for foreign private issuers and indicates that Evaxion Biotech A/S files its annual reports under Form 20-F. The filing does not contain specific financial figures or operational updates beyond its classification as a foreign private issuer.
Why It Matters
This filing confirms Evaxion Biotech's status as a foreign private issuer and its adherence to specific SEC reporting requirements, which is important for investors tracking its regulatory compliance.
Risk Assessment
Risk Level: low — This filing is a routine administrative report and does not contain new material financial or operational information that would typically increase risk.
Key Players & Entities
- Evaxion Biotech A/S (company) — Registrant
- 001-39950 (dollar_amount) — Commission File Number
- 20-F (company) — Annual Report Form
- 6-K (company) — Filing Form
FAQ
What is the purpose of this Form 6-K filing by Evaxion Biotech A/S?
The Form 6-K is a report of a foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, for the month of April 2025.
Does Evaxion Biotech A/S file its annual reports under Form 20-F or Form 40-F?
Evaxion Biotech A/S indicates by check mark that it files annual reports under cover of Form 20-F.
What is the Commission File Number for Evaxion Biotech A/S?
The Commission File Number for Evaxion Biotech A/S is 001-39950.
Where is Evaxion Biotech A/S's principal executive office located?
Evaxion Biotech A/S's principal executive office is located at Dr. Neergaards Vej 5f, DK-2970 Hoersholm, Denmark.
Is Evaxion Biotech A/S submitting this Form 6-K in paper format?
The filing does not explicitly state if it is submitted in paper format, but it notes the conditions under which a Form 6-K can be submitted in paper, which do not appear to be met by the content of this filing.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on April 28, 2025 regarding Evaxion Biotech A/S (EVAX).